Women who
are distressed because of hypoactive sexual desire could soon find relief
because of a new drug, Bremelanotide (BMT).
Female
Sexual Dysfunctions (FSD) encompasses multifactorial entities affecting about
10% of the population. Few treatment options exist to treat this condition.
auto-injector for Bremelanotide, Palatine Technologies |
Bremelanotide,
is a novel cyclic 7-amino acid melanocortin-receptor agonist with a high
affinity for the type-4 receptor. It increases levels of dopamine and
norepinephrine in medial preoptic area, thereby, modulating the brain pathways involved in sexual response.
The results
of two phase III trials were presented as a poster at the American Society of Clinical Psychopharmacology (ASCP) annual meeting, Florida May 29 – June 2,
2017.
The
RECONNECT study comprises 2 Phase 3, multicenter trials involving 1,247
premenopausal women with low sexual desire. The women were in stable,
monogamous relationship.
In this
intent to treat study, the women underwent a month screening period and a month
of treatment with a placebo so that the investigators could have an idea about
various baseline scores.
Women were
randomized to nearly 6 months of treatment with either self-administered BMT
(1.75 mg) or placebo subcutaneously using an auto-injector, as-desired, prior
to sexual activity. This was followed by an open label 52 weeks extension.
The control
and cases were assessed on various indices like the desire domain of the Female
Sexual Function Index (FSFI-D) and the Female Sexual Distress
Scale-Desire/Arousal/Orgasm (FSDS-DAO) score for feeling bothered by low sexual
desire; FSDS total and bother scores; Women’s Index of Treatment Satisfaction (WITS-9)
score; self-assessment of benefit, and satisfying sexual event (SSE) items of
the Female Sexual Encounter Profile-Revised (FSEP-R).
Besides significantly
improving the scores of all the indices, the women on BMT showed a significant
improvement in number of satisfying sexual events, arousal, lubrication and
orgasm. The women also reported feeling less distressed and more satisfied with
their sexual relations.
Most common
side effects encountered were nausea, vomiting, flushing, or headaches
resulting in 18% of women to discontinue the drug as compared to 2% in placebo group.
The average age
of the study participants was 39 years, more than 80% were white with a mean
BMI of 28.7 kg/m2 and most of them were suffering from hypoactive sexual desire
disorder (HSDD) with decreased arousal.
In 2015, FDA
approved the little pink pill or flibanserin (Addyi) a serotonin 1A receptor
agonist and a serotonin 2A receptor antagonist, as the first treatment for
hypoactive sexual desire disorder in premenopausal women.
The authors
concluded, “Treatment with BMT is associated with clinically meaningful and
statistically significant improvement in desire and a decrease in distress;
both hallmark characteristics of HSDD. BMT is an efficacious treatment for key
aspects of sexual function — desire, arousal, lubrication, and orgasm, in
premenopausal women.”
All the poster abstracts at the conference can be accessed here.
All the poster abstracts at the conference can be accessed here.
Please share more medicines for female.
ReplyDeleteGeneric Med Mart